

Multicentre, prospective, single-arm phase 3b/4 study. Patients with mild-moderate UC were treated with Multimatrix mesalazine 4.8 g/d for 8 weeks (induction phase). At w8, those who were in complete or partial remission were eligible to receive 12 months of MMX mesalazine 2.4g/d maintenance therapy.

Primary endpoint: Complete remission at month 12

Results: N=717; n=461 entered maintenance

- At week 8 25.9% and 39.3% of patients achieved complete and partial remission respectively.
- Likelihood of remaining in/achieve complete remission at month 12 was higher for those who entered maintenance being in complete remission vs partial 47.8% vs 26%, $p < 0.001$
- Mucosal healing (Mayo 0-1) at month 12: 76.4% and 63.5% of those who were in complete and partial remission respectively at end of induction.

Conclusion:

Patients achieving complete remission before dose reduction were more likely to remain in remission at Month 12.

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial

